We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Harald Sourij MD, MBA

Harald Sourij MD, MBA

Professor of Interdisciplinary Metabolic Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria

Harald Sourij is Full Professor for Interdisciplinary Metabolic Medicine, the Head of the Interdisciplinary Metabolic Medicine Trials Unit and Deputy Head of the Division of Endocrinology and Metabolism at the Medical University of Graz, Austria. After completing his studies sub auspiciis presidentis (summa cum laude) in 2004 and his training at the Medical University of Graz, Dr Sourij specialised as a consultant in internal medicine, as well as diabetes and endocrinology.

In 2010 Dr Sourij joint the Diabetes Trials Unit lead by Prof Rury Holman at the University of Oxford, UK, where he acted as the clinical lead for the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) until he returned to Graz, Austria in 2013.

Harald has published >150 manuscript listed in PubMed.

Disclosures

Dr. Sourij is on the advisory board and speaker’s bureau of Boehringer Ingelheim, NovoNordisk, Sanofi, Amgen, AstraZeneca, Bayer, Eli Lilly, Kapsch, MSD, and Daiichi Sankyo. H.S. received unrestricted research grants from Boehringer Ingelheim, Eli Lilly, MSD, NovoNordisk and Sanofi paid to the Medical University of Graz, Austria.